Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
  • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
  • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
  • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Definitions

• the present invention relates to a novel diphenylmethylbiperazine derivative, and particularly to a novel difluoromethylbiperazine derivative having an effect of suppressing myocardial hyperconstriction and hyperextension and protecting myocardium from death due to cardiomyopathy without having a cardiac inhibitory effect.
• 01 This relates to nilmethylpiperazine derivatives.
• the present invention also relates to a cardiovascular drug comprising the novel diphenylmethylbiperazine derivative as an active ingredient, and more particularly to a novel difuunylmethylpiperazine derivative as an active ingredient, which has a cardioplegic effect.
• the present invention relates to an inhibitor of myocardial necrosis, which can suppress hypercontraction and hyperextension of cardiac muscle and protect myocardium from necrosis, and a therapeutic and prophylactic agent for acute myocardial infarction.
• An object of the present invention is to provide a compound having a KD inhibitory action without a cardiac inhibitory action, an inhibitor of myocardial necrosis containing the compound as an active ingredient, and an agent for treating and preventing acute myocardial infarction.
• the present invention relates to a novel difujylmethylbiperazine derivative having a KD inhibitory action without a cardiac inhibitory action, in particular, a novel diphenylmethylpiperazine derivative having a specific binding group, and A pharmaceutically acceptable salt is provided, and a novel difuunyl methylpiperazine derivative having the specific binding group and an inhibitor of myocardial necrosis comprising the pharmaceutically acceptable salt thereof as an active ingredient; It provides therapeutic and prophylactic agents. That is, the compound according to the present invention
• the agent for suppressing myocardial necrosis and the agent for treating and preventing acute myocardial infarction each comprise one or two of a difluoromethylbiperazine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof. It contains more than one species as active ingredients.
• the novel diphenylmethylpiperazine derivative according to the present invention has a potent inhibitory action on myocardial necrosis without cardioplegic action, and is an excellent inhibitor of myocardial necrosis. It can be used as a therapeutic and prophylactic agent. Therefore, the present invention provides a drug capable of excellently suppressing myocardial necrosis and excellently treating and preventing acute myocardial infarction.
• salts of the compound represented by the formula [I] are also included in the scope of the compound according to the present invention.
• Such salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, and phosphates, and linoleic acid, citrate, maleate, fumarate, adipate, and benzoate.
• organic acid salts such as succinate, acetate and tartrate.
• the difluoromethylbiperazine derivative represented by the formula [I] of the present invention and a pharmaceutically acceptable salt thereof can be produced by a number of routes.
• the following route (A) or It can be produced by the reaction according to route (B).
• R in the reaction formula is as defined in the formula [I] of the present invention.
• the production method by the reaction of the route (A) can be represented, for example, by the following reaction formula.
• the compound represented by the formula [I] is as follows: 1- [1-1 (4-diphenylmethyl) biperazinyl] 13- [11- [41- (4-chlorophenyl) -14-hydroxy] piberidinyl] -2 —It is propanol.
• the compound represented by the formula [I] obtained by the production method by the reaction of the route (A) can be isolated and purified according to a conventional method.
• the starting material represented by the formula (a) can be prepared according to a conventional method for producing an epoxide compound.
• the compound represented by the formula (a) is converted into 11- (difuunylmethyl) piperazine [represented by the formula (c)] in a solvent with the reactant ebibromohydrin [formula (c ')]. Is reacted in the presence of sodium carbonate.
• the production method shown in the route ⁇ can be represented by, for example, the following reaction formula.
• the epoxide compound is 2- [1-1 (2,3-epoxy) propyl ] — 1,2,3,4-tetrahydroisoquinoline, and the reaction product obtained is 1-C2- (1,2,3,4-tetrahydro) isoquinolinyl) 1 3— [1 1 (4 1-diphenylmethyl) piperazinyl] -12-propanol.
• the starting material represented by the formula (2) can be synthesized in the same manner as the starting material (a) in the method for producing the reaction of the route (A).
• the diphenylmethylpiperazine thus obtained can be converted into various salt forms as described above by a conventional method.
• the diphenylmethylpiperazine derivative represented by the formula [I] and a pharmaceutically acceptable salt thereof according to the present invention have a KD inhibitory action, and It can be a therapeutic drug for organ diseases. Specifically, it is an anti-myocardial necrosis drug, and is useful as a drug for suppressing and preventing myocardial necrosis and a drug for treating and preventing acute myocardial infarction.
• the agent for inhibiting myocardial necrosis and the agent for treating and preventing acute myocardial infarction according to the present invention each comprise, as an active ingredient, one or more of the compound represented by the formula (I) and a pharmaceutically acceptable salt thereof. Including.
• the dose varies depending on the disease level, patient weight, administration route and the like, and is not particularly limited. Usually, an adult (average body weight 60 kg) can be administered orally or parenterally (for example, intravenously) at a dose of about 10 mg to about 1000 mg per day.
• the dosage form include powders, fine granules, tablets, capsules, and injections. In the case of formulation, it can be manufactured by an ordinary method using a usual formulation carrier or diluent.
• Hearts were removed from male rats weighing 300-380 g and perfused in a Langendorff manner at 80 cm water column pressure.
• the perfusate 1 ImM glucose including Krebs over Heng Ze Lai preparative-carbonochloridate 'I carbonate (Krebs-Henseleit bica rbonate) solution (37 ° C, pH 7.4) 95% to 0 2 + 5% C0 2 mixture It was used after gasification.
• the heart was beaten at 330 beats / min by electrical stimulation. After stabilization for 10 minutes, the test drug dose was perfused with a dissolved Kleps-Henseleit solution containing 5.5 mM calcium for calcium setting for 10 minutes, and then used as a trigger drug.
• a 1.5 ml aqueous solution containing 0.1 mg adrenaline was injected into the perfusate, a minute later, an lm 1 aqueous solution containing 10 mg caffeine was injected, and two minutes later, the heart was removed. Placed in formalin solution. The removed heart was cut horizontally at approximately 3 mm intervals after formalin fixation. Each cut block was dehydrated, defatted, embedded in paraffin as in a mold, cut at a thickness of 3 to 4 m, stained with Heidenhain iron hematoxylin staining solution, and a tissue specimen was prepared.
• the heart was excised from a male rat weighing 300 to 380 g and perfused at 80 cm water column pressure according to the Langendorff method under the same conditions as in the test method (1).
• the left ventricular pressure was measured by inserting a latex balloon into the left ventricle, and the heart rate was recorded from the beat.
• perfusion was performed with a perfusate containing the test compound for 10 minutes, and changes in cardiac function were recorded.
• Cardiac function was evaluated using the value of heart rate (HR) X left ventricular pressure (LVP) as an index. ⁇ Test results ⁇
• Table 1 shows the results obtained in Test Methods 1 and 2.
• the compound according to the present invention is a novel diphenylmethylpiperazine derivative, which has an action of suppressing myocardial hypercontraction and hyperextension without protecting the heart, and protecting the myocardium from necrosis.
• it Compared with conventional drugs for treating acute myocardial infarction, it has an excellent therapeutic and preventive effect on acute myocardial infarction, and has an excellent inhibitory and preventive effect on myocardial necrosis as a myocardial necrosis inhibitor .

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Heart & Thoracic Surgery (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Cardiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Luminescent Compositions (AREA)
• Other In-Based Heterocyclic Compounds (AREA)
• Hydrogenated Pyridines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=16112265

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (18)

Citations (2)

Family Cites Families (4)

• 1990
  • 1990-07-10 JP JP2182095A patent/JP2651043B2/ja not_active Expired - Lifetime
• 1991
  • 1991-07-10 AT AT91912316T patent/ATE112764T1/de not_active IP Right Cessation
  • 1991-07-10 EP EP91912316A patent/EP0541802B1/en not_active Expired - Lifetime
  • 1991-07-10 WO PCT/JP1991/000924 patent/WO1992000962A1/ja not_active Ceased
  • 1991-07-10 RU RU9192016555A patent/RU2091379C1/ru active
  • 1991-07-10 DE DE69104615T patent/DE69104615T2/de not_active Expired - Lifetime
  • 1991-07-10 CA CA002087032A patent/CA2087032C/en not_active Expired - Lifetime
  • 1991-07-10 US US07/958,366 patent/US5304558A/en not_active Expired - Lifetime
  • 1991-07-10 ZA ZA915366A patent/ZA915366B/xx unknown
  • 1991-07-10 AU AU82125/91A patent/AU8212591A/en not_active Abandoned
  • 1991-07-10 CN CN91105588A patent/CN1037840C/zh not_active Expired - Lifetime
  • 1991-09-03 TW TW080106989A patent/TW198717B/zh not_active IP Right Cessation

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events